Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 84

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 84
---
   |   765,330 |     |   |    461,865 |   |
| Total research and development expenses                 |     | $                       | 3,548,996 |     | $ | 4,145,902 |     | $ |   (596,906 | ) |

Research and development expenses decreased by $0.6 million, from $4.1 million for the year ended December 31, 2023 to $3.5 million for the year ended December 31, 2024. The decrease was primarily due to decreases of $2.1 million in other program expenses and $0.3 million in manufacturing expenses, offset by increases of $1.5 million in clinical study expenses related to our Product Candidates and $0.5 million in personnel expenses. Other program expenses include pre -clinicalcosts and clinical preparation costs primarily for our Product Candidates.

51

General and Administrative Expenses The following table summarizes our general and administrative expenses for the periods presented:

|                                                                  |     | Year Ended December 31, |      2024 |     |   |      2023 |     |   |   Change |   |
|:-----------------------------------------------------------------|:----|:------------------------|----------:|:----|:--|----------:|:----|:--|---------:|:--|
| Personnel expenses (including employee stock-based compensation) |     | $                       | 2,768,602 |     | $ | 2,272,005 |     | $ |  496,597 |   |
| Legal and professional fees                                      |     |                         | 1,274,567 |     |   | 1,844,077 |     |   | (569,510 | ) |
| Other expenses                                                   |     |                         |   382,944 |     |   |   394,680 |     |   |  (11,736 | ) |
| Total general and administrative expenses                        |     | $                       | 4,426,113 |     | $ | 4,510,762 |     | $ |  (84,649 | ) |

General and administrative expenses decreased by $0.1 million, from $4.5 million for the year ended December 31, 2023 to $4.4 million for the year ended December 31, 2024. The decrease was primarily due to a decrease of $0.6 million in legal and professional fees, offset by an increase